| Overview |
| bs-11339R-Cy3 |
| CLSTN2 Polyclonal Antibody, Cy3 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Cow, Pig, Horse, Chicken, Rabbit |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CLSTN2 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Cell membrane |
| Alc; Alcadein; Alcadein Gamma; Alcagamma; Alzheimer's disease related cadherin like protein; Calsyntenin 2; CLSTN 2; CS 2; CS2; FLJ39113; FLJ39499; MGC119560; CSTN2_HUMAN. |
| Members of the calsyntenin protein family are localized to the post-synaptic membrane of exicitatory central nervous system (CNS) synapses. Calsyntenin-2, also known as Alcadein-gamma, is a 955 amino acid protein that localizes to the endoplasmic reticulum, golgi apparatus and plasma membranes. Containing 2 cadherin-like repeats in its N-terminal extracellular region, calsyntenin-2 binds synaptic calcium with its cytoplasmic domain, suggesting a role in the modulation of calcium-mediated postsynaptic signals. Under normal physiological conditions, calsyntenin-2 is protoeolytically processed in an event in which the primary zeta-cleavage generates a short C-terminal transmembrane fragment and a long extracellular N-terminal domain. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |